No description available.

Submitted in partial fulfillment of the requirements for the degree of Doctor of Technology: Clinical Technology, Durban Institute of Technology, 2005. / Fumonisin B1 (FB1) and ochratoxin A (OTA) represent examples of mycotoxins of greatest public health and agro-economic significance. They exert adverse effects on humans, animals and crops that result in illnesses and economic losses. Fumonisin B1 are cancerpromoting metabolites of Fusarium proliferatum and F verticillioides, (formerly moniliforme), and are implicated in oesophageal cancer. Ochratoxins are metabolites of both Aspergillus and Penicillium species. These compounds are known for their nephrotoxic effects in all animal species and may promote tumours in humans. In man OTA exhibits unusual toxicokinetics, with a half-life in blood of 840 h (35 days) after oral ingestion. Although much is known regarding the toxicology of these toxins, little is known of the effects of these toxins on the immune system. The aim of this study was to determine and compare the immunornodulating effects of FB1 and OTA in human carcinoma. Initial experiments involved isolating lymphocytes and neutrophils from healthy volunteers. The isolated cells were exposed to either FB1 or OTA on a dose and time dependent level and LD50 of the toxins was determined. Thereafter, challenge tests were performed, whereby lymphocytes and neutrophils isolated from volunteers, oesophageal cancer patients and breast cancer patients were exposed to the LD50 dose of either FB1 or OTA for the appropriate time. The effect of the toxins was demonstrated by viability studies, light microscopy and electron microscopy. Cytokine receptors (CK, TNF and CSF) were evaluated by immuno-cytochemical methods and the levels of circulating cytokines (IL -1, IL-6, IL-8, IL-10 and TNF-a) were determined using ELISA kits. / D

The main goal of this project was the development of carbon nanotubes as a candidate for dual-functioning magnetic hyperthermia structure and magnetic resonance imaging contrast agent. This was achieved by filling carbon nanotubes with continuous ferromagnetic α-Fe nanowires and surface functionalized with paramagnetic Gd(III). Also, length control of both nanotube and nanowire was investigated. Firstly, a low vapour flow-rate and constant evaporation temperature chemical vapour deposition method based on the thermal decomposition of ferrocene was employed which achieved continuous α-Fe nanowires on the same scale as the nanotube for lengths >10 m without the necessity of post-synthesis heat-treatment or introduction of other precursor elements. The low vapour flow-rate regime has the advantage of sustaining the intrinsic temperature gradient at the tip of the forming structure which drives the vapour feedstock to the growth front to guarantee continuous nanowire formation. For initially mixed-phase nanowires of length less than 10 μm, the continuous α-Fe nanowires were achieved by postsynthesis heat treatment. Secondly, a simple wet chemical method involving only sonication in aqueous GdCl3 solution was used for surface functionalization of iron-filled multiwalled carbon nanotubes with gadolinium. Functional groups on the sidewalls produced by the sonication provide active nucleation sites for the loading of Gd3+ ions. Characterization by electron paramagnetic resonance, electron energy loss spectroscopy, and high-resolution transmission electron microscopy confirmed the presence of Gd3+ ions on the sidewall surface. The ferromagnetic properties of the encapsulated iron nanowire maintained after surface functionalization. At room temperature a saturation magnetization of 40 emu/g and a coercivity of 600 Oe were observed. Heating functionality in an alternating applied magnetic field was quantified through the measurement of specific absorption rate: 50 W/gFe and the intrinsic loss power: 1.12 nHm²kg⁻¹ at magnetic field strength 8 kA/m and frequency of 696 kHz. These structures exhibited an extremely high relaxivity r₁ ~ 200 mM⁻¹ s⁻¹ at high magnetic field (9.4 T).

Mammographic density (MD), created predominantly by increased stromal tissue, is a major breast cancer risk factor, though little is known about the biological mechanisms mediating it. Tamoxifen prevents breast cancer in a subset of high risk women via mechanisms that appear dependent on reduction of MD. Animal models suggest tamoxifen remodels the mammary stroma to a tumour-inhibitory phenotype. This study aims to analyse the effect of tamoxifen on human breast fibroblast function and identify pro-tumourigenic pathways contributing to density-associated risk. Methods Primary human breast fibroblasts from normal, high risk or breast cancer patients were treated with hydroxytamoxifen (100nM-5μM). Fibroblast function was analysed by measuring: proliferation, expression of stromal proteins fibronectin and collagen 1; effects on TGF-β signalling and up-regulation of myofibroblast marker SMA. Genome wide analysis was performed using RNA-Seq. Significantly deregulated pathways were validated by PCR, western blotting and mass spectrometry. Results Fibroblasts from 23 patients were treated with hydroxytamoxifen. All patients showed reduced proliferation with treatment. 62% of patients showed reduced fibronectin expression. TGF- β-mediated up-regulation of SMA and fibronectin were consistently inhibited by tamoxifen. RNA-Seq analysis revealed down-regulation of Wnt signalling, an established profibrogenic and pro-tumourigenic pathway. In addition, there was significant modulation of many metabolic pathways, including components of the microsomal anti-oestrogen binding site (AEBS). Binding of tamoxifen to the AEBS inhibits cholesterol epoxide hydrolase (ChEH) enzyme activity, promoting an anti-tumourigenic phenotype. The effects of tamoxifen on fibroblasts could be partly replicated using tesmilifene, a commercially available 5 inhibitor of ChEH. Mass spectrometry analysis confirmed an altered cholesterol metabolite profile in tamoxifen treated fibroblasts. Conclusion These data indicate that tamoxifen can directly remodel the mammary stromal microenvironment, generating a less 'reactive' stroma. Thus, tamoxifen impacts on multiple pathways, many independent of the oestrogen receptor, to create a tumourinhibitory microenvironment. This offers exciting potential for patient monitoring and alternative breast cancer prevention strategies.

Fibroblasts are abundant mesenchymal cells present in all tissues in a quiescent state, which contribute to wound healing when activated. Cytokine transforming growth factor-β1 (TGF-β1) stimulates fibroblast-myofibroblast differentiation, which induces extracellular matrix secretion, tissue contraction and promotes cancer cell migration. Hence, chronic activity of stromal myofibroblasts correlates with a poor prognosis for cancer and organ fibrosis patients. Therefore, modulating myofibroblast activity may reduce the severity of these diseases. Previous research suggests blockade of transmembrane integrin receptors expressed by fibroblasts prevents TGF-β1- induced differentiation, indicating integrins are attractive therapeutic targets. However, fibroblasts derived from different organs exhibit heterogeneity, although their integrin expression and integrin-regulated differentiation has not been directly compared. The aim of my research was 1) to understand and compare how integrins regulate TGF-β1-induced activation of fibroblasts derived from normal skin, lung and breast tissue; 2) to examine the global gene expression of TGF-β1-treated lung fibroblasts; 3) to identify novel therapeutic targets that modulate TGF-β1-induced activation of lung fibroblasts using a drug library. qPCR showed skin, lung and breast fibroblasts differentially expressed TGF-β1- induced activation markers, including ACTA2, FN1, TIMP3, CTGF and SERPINE1, in addition to integrin genes for α1, α4, α11 and β3. Small-molecule inhibitors of αv integrins only reduced the invasion of TGF-β1-exposed skin fibroblasts, but not lung or breast fibroblasts. siRNA against α11, β3 and β5 decreased TGF-β1-induced collagen contraction and activation marker expression in skin and lung fibroblasts, while α1 siRNA prevented collagen contraction by breast fibroblasts only. RNA sequencing of TGF-β1-treated lung fibroblasts revealed pro-inflammatory and profibrotic pathways were significantly enriched, while screening TGF-β1-treated lung fibroblasts with a FDA-approved drug library identified 46 hits that significantly reduced α-smooth muscle actin and fibronectin expression. Overall, genes are differentially expressed in TGF-β1-treated skin, lung and breast fibroblasts, while different integrins in each fibroblast appear to regulate invasion, TGF-β1-induced collagen contraction and gene expression. RNA sequencing revealed TGF-β1 promotes the expression of a pro-tumour signature in lung fibroblasts and several novel therapeutic targets that modulate the activation of lung fibroblasts have been identified. Understanding these integrin-dependent and independent mechanisms will facilitate the generation of myofibroblast-targeted treatments for cancer and organ fibrosis.

No description available.

M.Tech. / Natural occurring components in human breast milk, cow milk and soy milk have shown anticarcinogenic abilities. The human breast milk protein, -lactalbumin, was found to induce apoptosis in cancer cells, embryonic cells and rapidly growing cells, when converted from its native form to a partial denatured apoptotic-inducing form. Moreover, radiation may cause irreversible changes of protein conformation at the molecular level. Native -lactalbumin is one protein that has shown a decrease in aromatic amino acid concentration and the formation of high and low molecular weight fractions when exposed to high doses of ionizing radiation. The effect of human breast milk, cow milk, soy milk and galactose (positive control) on SNO, A549 cancer cells and normal lymphocytes were investigated. Human breast milk was irradiated with low doses of Co60 ionizing radiation (0.1Gy, 1.0Gy and 5.0Gy) in order to establish the effect of these doses on the apoptotic-inducing ability of human breast milk. The techniques used included, Trypan blue dye exclusion (cell viability), haematoxylin and eosin stain (cell morphology), modified comet assay (halo) (DNA damage) and flow cytometry (apoptosis and necrosis). Findings showed that human breast milk, irradiated human breast milk and galactose induced apoptosis in the SNO, A549 cells and lymphocytes. The cell viability, cell morphology and DNA fragmentation patterns of irradiated human breast milk were similar to that of non-irradiated human breast milk, although the flow cytometry results did not correlate. Cow and soy milk did not induce apoptosis in the SNO, A549 cells and lymphocytes. The modified comet assay (halo) detected DNA damage as apoptotic or necrotic cells. A clear distinction could not be made between the two cell populations using this assay. Flow Cytometry discriminated and quantified apoptotic cells and necrotic/late apoptotic cells using Annexin V and Propidium Iodide (PI), respectively.

No description available.

Considerable interest exists with regard to the putative therapeutic role of ascorbic acid in various conditions. A condition which has received much attention is cancer, as it is reported that ascorbic acid may be a prophylactic against cancer development. However, the actual involvement of ascorbic acid, an oxidizing/reducing agent, in the development and progression of tumours is presently a subject of much speculation. This study initially addressed the effect of ascorbic acid supplementation over a nutritional concentration range (0 - 100 μg/ml) on the in vitro growth of non-malignant LLCMK and malignant B16 cells. Ascorbic acid supplementation of these two cell types resulted in an overall decrease in the growth of both types of cells. The actual inhibitory mechanism of ascorbic acid on cell growth was not clear. Further study attempted to define and explain a mechanism responsible for this effect. Ascorbic acid has a role in the maintenance of tissue integrity and host defences, thus providing a rational basis for examining its relationship to cancer. Ascorbic acid is lcnown to be essential for the structural integrity of the intercellular matrix of the cells, the latter being a complex aqueous gel containing, amongst other compounds, fats and prostaglandins. Fats and prostaglandins have diverse effects on. membrane stability, enzyme activity and secondary messengers within cells. Hence, this study investigated the effect of ascorbic acid supplementation on certain enzymes and secondary metabolites within the cells, which had the potential to be involved in the control of cell growth. Throughout this study, emphasis was placed on the Bl6 melanoma cells as ascorbic acid supplementation did not significantly affect levels of secondary metabolites within the non-malignant LLCMK cells. Ascorbic acid supplementation of the B16 cells resulted in significant increases in adenylate cyclase activity and cyclic adenosine monophosphate levels, witb a significant decrease in Bl6 cell growth in that particular experiment. As cyclic adenosine monophosphate has a regulatory role in the cell cycle, this study suggested that the inhibitory effect of ascorbic acid supplementation on cell growth was mediated tbrough a final effect provided by the second messenger, cyclic adenosine monophosphate. However, clarification of tbe mechanism of tbe effect of ascorbic acid on adenylate cyclase activity was required. Hence, a further study investigated prostaglandin E₂ levels, as tbese affect adenylate cyclase activity. Prostaglandin E₂ levels were also found to be inversely related to Bl6 cell growth with ascorbic acid supplementation. It thus appeared tbat adenylate cyclase activity was dependent on prostaglandin E₂ levels in the B16 cells, and further study showed that tbis was indeed the case. Here, higher levels of prostaglandin E₂ supplementation of the Bl6 cells inhibited cell growth significantly and also significantly increased adenylate cyclase activity. Arachidonic acid is the precursor of prostaglandin E₂. In the presence of ascorbic acid supplementation, the percentage arachidonic acid composition of the Bl6 cells was inversely correlated with cell growth. Hence, prostaglandin E₂ levels in ascorbic acid supplemented B16 cells appeared dependent on tbe amount of precursor present. This was confirmed when Bl6 cells were supplemented with arachidonic acid. The latter had an inhibitory effect on Bl6 cell growth and also stimulated prostaglandin E₂ production. The cause of tbe inverse relationship between B16 cell growth and arachidonic acid composition with ascorbic acid supplementation was furtber investigated and found to be dependent on tbe uptake of arachidonic acid and other essential fatty acids from tbe medium. The enzymes phospholipase A₂ delta-5 and delta-6-desaturase, and elongase which could influence arachidonic acid levels were not affected to any extent by ascorbic acid supplementation and therefore did not influence the inverse relationship between B16 cell growth and arachidonic acid. Hence, it can be concluded that the effect of ascorbic acid supplementation on the BI6 cells is mediated, in part at least, by cyclic adenosine monophosphate. However, this is not the result of a direct effect of ascorbic acid supplementation. The initial effect of ascorbic acid supplementation concerns fatty acid - in particular arachidonic acid - uptake from the medium, with subsequent cascade effects On secondary metabolites, ultimately affecting the cellular levels of cyclic adenosine monophosphate.

The present study was carried out to determine the effects and possible mechanism of action of zinc supplementation on the in vitro growth of malignant murine melanoma (B16) and non-malignant monkey kidney (LLCMK) cells. Cell culture studies showed that zinc supplementation significantly inhibited B16 growth at all the concentrations studied (1, 3, 5 and lOμg/ml). Zinc was also found to inhibit the growth of the LLCMK cells, although to a lesser extent than the B16 cells. Possible evidence of mobilisation of the essential fatty acids from the membrane phospholipid stores was noted in both cell types. This effect was, however, greater in the B16 cells. Δ⁶-desaturase activity was found to be significantly lower in the B16 cells than in the LLCMK cells (p ≥ 0.05). Zinc supplementation resulted in an increase in the enzymes activity in the LLCMK cells and, at high concentrations, in the B16 cells. An estimation of elongase and Δ⁶-desaturase activity with zinc supplementation indicated that zinc had little or no effect on the activity of these enzymes. B16 cells were found to have higher levels of free radicals than the LLCMK cells. Zinc supplementation resulted in increased free radical formation in the B16 cells, while no effect was observed in the LLCMK cells. Lipid peroxidation increased in both cell types with increased zinc concentrations. The observed effect of zinc supplementation on cell growth may involve these elevated levels of lipid peroxides. CycIo-oxygenase activity was found to be greater in the B16 cells than the LLCMK cells. The activity of the enzyme increased with higher concentrations of zinc (lOμg/ml) in both cell types. Prostaglandin E, levels were found to be lower in the B16 cells compared to the LLCMK cells. The levels of prostaglandin E, in both cell types appeared to be dependent on the levels of the polyunsaturated fatty acid precursors to the prostaglandins. Zinc was found to inhibit the activity of the enzyme adenylate cyclase in both cell types. The cAMP levels in the LLCMK cells were also found to decrease with zinc supplementation. In the case of the B16 cells, cAMP levels increased at low concentrations of zinc despite a decrease in adenyl ate cyclase activity, suggesting a possible inhibition of cAMP phosphodiesterase activity at these concentrations of zinc. It is concluded that although zinc supplementation does have an effect on cell growth, this effect is not mediated through the activation of adenylate cyclase by the prostaglandins resulting in elevated levels of cAMP. A possible mechanism involving lipid peroxidation is proposed.